NEW YORK (GenomeWeb News) - Caris Diagnostics has agreed to buy Molecular Profiling Institute for an undisclosed sum, Caris said yesterday.
Caris, which has a facility in Tempe, Ariz., said it expects to maintain that presence as well as MPI’s headquarters, which are located in Phoenix.
MPI is a reference lab that offers prognostic testing services and genomic and proteomic profiling for cancer and other complex diseases. Its proprietary offerings include Target Now, a late-stage cancer panel; Mammostrat, an early-stage breast cancer test; and CardioEvaluatR, which is a cardiovascular disease management panel.
MPI also has a Tissue Banking and Analysis Center offering biospecimen procurement, tracking, storage, analysis, and reporting for diagnostics and pharmaceutical companies and medical centers.
"Caris Diagnostics enhances our ability to provide more robust analysis, repository functions, and distribution to patients across the country," MPI CEO Robert Penny said in a statement.
Financial terms of the agreement were not released.